Tesamorelin
A growth-hormone-releasing peptide FDA approved as Egrifta to reduce excess abdominal fat in certain adults.
- Vial
- 2.0 mL
- Strength
- 5.0 mg/mL
- Typical dose
- 1.0 mg (20 units)
- Schedule
- Once daily
- Per vial
- About 10 doses
- FDA status
- FDA approved as Egrifta for one specific use
What it is
Tesamorelin is a growth-hormone-releasing hormone analog. It signals the pituitary gland to release growth hormone, which in turn reduces deep abdominal (visceral) fat.
What the research shows
The FDA approved tesamorelin in 2010 as Egrifta to reduce excess abdominal fat in adults with HIV who have lipodystrophy. Clinical trials showed reductions in visceral fat. Other uses are off-label.
How it's used
Tesamorelin is commonly supplied as a 2.0 mL vial at 5.0 mg/mL. A typical dose is 1.0 mg (20 units), injected under the skin, once daily. Your prescriber sets your exact dose and schedule.
Common questions
Does it affect blood sugar?
I
t
c
a
n
r
a
i
s
e
b
l
o
o
d
s
u
g
a
r
i
n
s
o
m
e
p
e
o
p
l
e
,
s
o
y
o
u
r
p
r
e
s
c
r
i
b
e
r
m
a
y
c
h
e
c
k
i
t
d
u
r
i
n
g
t
r
e
a
t
m
e
n
t
.
How long until I see results?
I
n
c
l
i
n
i
c
a
l
t
r
i
a
l
s
,
c
h
a
n
g
e
s
i
n
a
b
d
o
m
i
n
a
l
f
a
t
w
e
r
e
m
e
a
s
u
r
e
d
a
f
t
e
r
s
e
v
e
r
a
l
m
o
n
t
h
s
o
f
d
a
i
l
y
u
s
e
.
Is it safe?
E
v
e
r
y
p
e
p
t
i
d
e
h
a
s
p
o
s
s
i
b
l
e
s
i
d
e
e
f
f
e
c
t
s
,
a
n
d
m
a
n
y
h
a
v
e
l
i
m
i
t
e
d
l
o
n
g
-
t
e
r
m
r
e
s
e
a
r
c
h
i
n
p
e
o
p
l
e
.
Y
o
u
r
p
r
o
v
i
d
e
r
r
e
v
i
e
w
s
y
o
u
r
h
e
a
l
t
h
h
i
s
t
o
r
y
b
e
f
o
r
e
p
r
e
s
c
r
i
b
i
n
g
a
n
d
c
a
n
e
x
p
l
a
i
n
t
h
e
r
i
s
k
s
f
o
r
y
o
u
.
Good to know
- Available by prescription only, after an evaluation by a licensed provider.
- FDA approved only for the specific use above; other uses are off-label.
- If you compete in a sport that drug-tests, this peptide is on the World Anti-Doping Agency (WADA) prohibited list.
- See the side-effect guide for what to watch for.
